YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC₅₀s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease^[1]. IC50 & Target: EC50: 2.75 μM (CBP), 29.04 μM (PCAF), 49.31 μM (GCN5)^[1] In Vitro: YF-2 (0.03, 0.1, 0.25, 0.5, 1, 2.5, 5, 15, 40 and 80 μM, 72 hours) inhibits the preliferation of U251, CCRF-CEM, Hs578T, NCI-ADR-RES cells^[1]. In Vivo: YF-2 (20 mg/kg, 2 hours befor electric shock or 5 mg/kg, 30 min before the electric shock, i.p.) rescues the defect in contextual memory in mice, and shows no effect on contextual memory alone at 20 mg/kg in mice^[1].